Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 35
- Registration Number
- NCT02941354
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.
Phase 1
Completed
- Conditions
- ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: NNC9204-1177Drug: Placebo
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT02941042
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Baltimore, Maryland, United States
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 68
- Registration Number
- NCT02938585
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Hangzhou, Zhejiang, China
A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 47
- Registration Number
- NCT02938572
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT02933853
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT02920398
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Málaga, Spain
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.
Phase 1
Completed
- Conditions
- HealthyDiabetes
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT02920385
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
Phase 3
Completed
- Conditions
- ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 251
- Registration Number
- NCT02918279
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 210
- Registration Number
- NCT02911948
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yamaguchi-shi, Yamaguchi, Japan
A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT02911870
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath